NCT04661839 - A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 24, 2020

Primary Completion Date

July 27, 2021

Study Completion Date

July 27, 2021

Conditions

COVID-19

Interventions

BIOLOGICAL

COVID-HIGIV

COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion.

OTHER

Placebo (saline)

The reference product is a liquid solution of normal saline (0.9% weight per unit volume (w/v) sodium chloride). Placebo will be administered via intravenous infusion.

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York